



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Medicure, Inc.	Examiner:	Dwayne C. Jones
Serial No.:	10/639,948	Group Art Unit:	1614
Filed:	August 12, 2003	Docket No.:	12695.6USD6
Title:	TREATMENT OF CARDIOVASCULAR AND RELATED PATHOLOGIES		

---

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form PTO-1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits, but before the mailing date of a final action under 37 C.F.R. § 1.113. In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

10/07/2004 JBALINAN 00000135 10639948


01-FC:2253 490.00-DA  
02-FC:1806 180.00 DA

10/07/2004 JBALINAN 00000024 132725 10639948  
Sale Ref: 00000135 DAH: 132725 10639948  
01-FC:2253 490.00-DA  
02-FC:1806 180.00-DA


Please charge Deposit Account No. 13-2725 in the amount of \$180.00 for consideration of the items listed on the enclosed Form PTO-1449. A duplicate copy of the Transmittal Sheet is enclosed for this purpose.

Respectfully submitted,

Date: October 6, 2004

  
Ronald A. Daignault  
Reg. No. 25,968

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
202-625-8380



FORM 1449\*

## INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12695.6USD6


Application Number:

10/639,948

Applicant: Medisure, Inc.

Filing Date: August 12, 2003

Group Art Unit: 1614



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Kuo & Wang, "Pyridoxal Phosphate-Responsive Epilepsy with Resistance to Pyridoxine," <i>Pediatric Neuro.</i> , 26(2):146-147 (2002).
		Onorato, <i>et al.</i> , "Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions," <i>J. Biol. Chem.</i> , 275(28):21177-21184, July 14, 2000.
		Schaumburg, <i>et al.</i> , "Sensory Neuropathy from Pyridoxine Abuse," <i>N. Eng. J. Med.</i> , 309(8):445-448, August 25, 1983.
		Yamashima, <i>et al.</i> , "Neuroprotective Effects of Pyridoxal Phosphate and Pyridoxal Against Ischemia in Monkeys," <i>Nutritional Neuroscience</i> , 4:389-397 (2001).

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.